Please assess the completion status of the following clinical trial:

Trial Title: Efficacy of Laser Debridement on Pain and Bacterial Load in Chronic Wounds

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Aged eighteen years or older~* Having a chronic wound (as defined by lack of at least 50% reduction in wound surface area over a period of four weeks)~* No clinical evidence of active wound bed infection~* No exposure of any vital structure (i.e., tendon, bone, vessel)~* Has signed the informed consent form prior to any study protocol related procedure~* Willing and able to adhere to protocol requirements~Exclusion Criteria:~* Any unstable medical condition that would cause the study treatment to be detrimental to the subject, as judged by the Principle Investigator~* Documented medical history of significant cardiac, pulmonary, gastrointestinal, endocrine (other than Diabetes Mellitus type 1 or 2), metabolic, neurological, hepatic or nephrologic disease would impede the subject's participation, as judged by the Principle Investigator~* Documented medical history of immunosuppression, immune deficiency disorder, or currently using immunosuppressive medications~* Having clinical presentation of active osteomyelitis~* Pregnancy or lactation~* Participation in another clinical study involving ulcers within thirty days prior to enrollment

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Week 1 - Erbium:Yttrium-Aluminum-Garnet Laser Debridement (Type: ACTIVE_COMPARATOR): During the first treatment, laser debridement will be performed at 200-um until punctate bleeding is visualized. During the second treatment, sharp debridement will be performed via a scalpel/curette until punctate bleeding is visualized.~Tissue biopsies will then be obtained from the wounds prior to the first treatment, immediately after the first treatment, immediately prior to the subsequent treatment, and immediately after the second treatment. These will then be sent to Pathogenius for molecular analysis of wound microflora using polymerase chain reaction and sequencing.~Pain will be assessed during debridement by recording the Numerical Rating Scale for pain assessment.
- Week 1 - Scalpel/Curette Debridement (Type: ACTIVE_COMPARATOR): During the first treatment, sharp debridement will be performed via a scalpel/curette until punctate bleeding is visualized. During the second treatment, laser debridement will be performed at 200-um until punctate bleeding is visualized.~Tissue biopsies will then be obtained from the wounds prior to the first treatment, immediately after the first treatment, immediately prior to the subsequent treatment, and immediately after the second treatment. These will then be sent to Pathogenius for molecular analysis of wound microflora using polymerase chain reaction and sequencing.~Pain will be assessed during debridement by recording the Numerical Rating Scale for pain assessment.

Based on this trial design, predict the completion outcome and termination type (if applicable).